Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cuba claims magnetotherapy success for PID (pelvic inflammatory disease):

This article was originally published in Clinica

Executive Summary

Cuba could soon be using magnetotherapy to treat pelvic inflammatory disease (PID) across the national health system, following positive results from a trial of a "local magnetic stimulator" developed by the national applied electromagnetism centre (CNEA). A study of some 300 women treated with the NAK-02 device in combination with a pharmacological regime is said to have shown "greater curative effect (a rapid reduction in pain, fever and other discomfort), in less time and without adverse reactions" than alternative regimens. The Santiago de Cuba-based CNEA's device was trialled at the city's Hospital Materno Tamara Bunke, in a project headed by Dr Carlos Corral. An estimated 70% of Cuban women of fertile age are said to have had some form of PID. Cuba has the manufacturing capacity to meet national demand for the device, according to the ACN news agency.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel